Actelion 2016 net income disappoints, despite significant increase

14 February 2017

Switzerland’s Actelion (SIX: ATLN) this morning announced its results for the full year 2016, reporting that net income rose 26% (+19% at constant exchange rates) to 696 million Swiss francs ($693.4 million), but missing the average estimate of 737 million francs in a Reuters poll of analysts.

Actelion’s shares were barely changed, dipping just 0.26% to 269.00 francs by late morning trading.

US generally accepted accounting principles (GAAP) operating income grew to 789 million francs (+14% at CER) and core operating income increased to 992 million francs (+17% at CER), said Actelion, Europe’s largest biotech firm and subject to an agreed acquisition by Johnson & Johnson (NYSE: JNJ) for $ 30 billion with spin-out of new R&D company, listed on Swiss stock exchange.Sales for 2016 rose 18% (+15% at CER) to 2.42 billion francs, in line with the 2.41 billion francs expected in a Reuters poll.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK